ERBB2 and gastric cancer: The human epidermal growth factor receptor 2 (HER2) antibody trastuzumab could be used as the first line treatment combined with chemotherapy, and displays dramatically improved survival in GC and GEJ patients with high HER2 expression (median OS: 16 months vs. 11.8 months)3.